Hey Superheroes,
Wall Street staged a sharp recovery on Thursday 17 September, the day after the Federal Reserve raised rates 25 basis points to a target range of 3.75% to 4.00%, its first hike since 2023. The S&P 500 rose 1.12% to 7,636.21, the Nasdaq gained 1.60% to 26,395.18 and the Dow added 0.67%, a rebound that suggested traders had already priced in the move and were not bracing for an aggressive series of further hikes.
Bond markets settled alongside equities. The US 10-year Treasury yield eased to 4.93% from a Wednesday peak near 5.02%, as investors interpreted the move as a calibration rather than the start of a sustained tightening cycle. Trading Economics confirmed the pullback.
Oil gave back ground for a second straight session. Brent crude fell to US$104 a barrel after Saudi Arabia signalled it could restore part of a damaged pipeline’s capacity, easing supply concerns tied to the ongoing Middle East conflict.
Foundation cracks
Lennar Corporation (NYSE:LEN), one of America’s largest residential homebuilders, buys land, builds homes and sells them across more than 20 US states. The model is straightforward. When rates rise, buyers step back and Lennar sells fewer homes at lower prices. That dynamic has been playing out all year, and this week’s result confirmed it is not letting up.
The numbers
Lennar reported Q3 FY26 adjusted EPS of US$1.23 against a consensus estimate of US$1.29, with GAAP EPS of US$1.19. Revenue fell 9% year on year to US$8.05 billion, short of the US$8.31 billion estimate. New home orders also fell 9% to 20,840 homes at an average sale price of US$372,000. Shares fell 2.8% following the release.
The guidance
The company cut its full year 2026 delivery target to a range of 80,000 to 81,000 homes, down from a prior range of 82,000 to 83,000. Executive Chairman, CEO and President Stuart Miller said results reflect “the nature of the environment in which the company is operating, which has deteriorated since the last earnings call.”
What the numbers don’t tell us
The miss arrives at a complicated moment for US housing. The Fed’s rate hike this week puts further upward pressure on mortgage rates, adding to affordability constraints that were already evident in Lennar’s volume declines. Lennar is one of the largest homebuilders in the country, so a delivery target cut signals sector-wide strain rather than a company-specific stumble. Whether the market reads this week’s Fed move as truly one and done will matter enormously for the sector’s near-term outlook.
How has JHX absorbed the AZEK business
James Hardie Industries (ASX:JHX) has been working to demonstrate that its AZEK acquisition can deliver meaningful financial returns. At its first investor day since completing that deal, on 15 September, the company offered upgraded long-term targets. The share price reaction suggested investors wanted more near-term certainty than the update provided.
The numbers
James Hardie lifted its FY27 free cash flow target by roughly 20% to approximately US$600 million, up from a prior floor of US$500 million. Free cash flow conversion is now targeted at around 38% in FY27, compared with 30% in FY26. The company also said its US$125 million AZEK cost synergy target is now expected roughly a year ahead of schedule. Net leverage is targeted below 2.0 times by fiscal Q2 2028.
What James Hardie said
The company reaffirmed its FY27 net sales and adjusted EBITDA guidance excluding Europe, framing the investor day as a longer-term framework update rather than a near-term earnings upgrade. That framing appears to be what disappointed the market.
What the numbers don’t tell us
A 5.2% share price fall on a day management lifted long-term targets tells its own story. Investors appear to be applying a “show me” discount, upgraded free cash flow guidance is positive, but with AZEK integration still playing out and interest rate conditions weighing on US construction activity, near-term earnings momentum has not yet followed the guidance higher. The gap between improved long-term targets and unchanged near-term forecasts is where market patience is wearing thin.
Some other things we’re shining the Spotlight on:
St Barbara sells Simberi stake to China’s Lingbao Gold for A$410m
St Barbara (ASX:SBM) struck a binding deal to sell its Simberi stake to China’s Lingbao Gold Group for A$410 million in cash plus a A$43 million capital repayment. Completion is targeted for the March 2027 quarter, subject to Chinese and Papua New Guinean regulatory approvals and a shareholder vote. St Barbara retains a 2.75% net smelter royalty on future gold and silver production and a 1.5% royalty on exploration licence output, both commencing July 2027.
FDA approves Telix’s Pixclara brain cancer scan, UBS cuts price target
Telix Pharmaceuticals (ASX:TLX) announced on 14 September that the FDA approved Pixclara, an FET-PET imaging agent and the first approved scan of its kind for glioma, a form of brain cancer. Despite the landmark approval, shares fell around 5% on 16 September after UBS cut its price target to A$22 from A$31, suggesting the market had already priced in the regulatory milestone and was refocusing on the commercialisation timeline ahead.
Senate blocks Clarity Act, crypto ETFs shed US$592m in a single day
The US Senate voted 50-49 to block the Clarity Act crypto market structure bill on 15 September, short of the 60 votes needed to advance. Bitcoin ETFs shed US$450 million the same day, the largest outflow since 25 June, led by Fidelity’s FBTC and BlackRock’s IBIT. Combined with Ethereum ETF outflows, total crypto ETF redemptions reached roughly US$592 million.
Keep up to date on the markets by following us on Instagram @superheroau.
